SCIEX, a life science analytical technology company and QPS Holdings, a full-service Contract Research Organization (CRO), announced the collaboration yesterday.
SCIEX provides support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry to clients focusing on basic research, drug discovery and development, food and environmental testing, forensics, and clinical research.
The new joint venture will work to advance Hybrid LBA –LCMS, a workflow for routine biologics quantification. Per the agreement, QPS Holdings will deploy SCIEX’s BioBA Solution, wich the companies describes as “the first end-to-end and most complete solution for bioanalysis of biologics.”
According to the company, as the industry continues to develop more large molecule therapies, new challenges will continue to arise, including characterizing and quantifying large molecules such as peptides, proteins, monoclonal antibodies, oligonucleotides, and antibody drug conjugates in complex biological matrices.
The BioBA solution includes ready-to-use sample preparation kits, a fully automated liquid sample handler, a LC component, and a QTRAP MS System with software for performing bioanalytical studies designed to support CFR 21 part 11 compliance.
“The integrated BioBA solution enables scientists transitioning from traditional small molecule bioanalysis to biologics, to generate robust, reproducible and high-quality data,” said Farzana Azam, Senior Director of Pharma/CRO Business at SCIEX. “BioBA empowers scientists to turn the complexities of biologics bioanalysis into a simple process for both experts and non-experts, making the transition from small to large molecules easier than you think.”